GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Piotroski F-Score

Journey Medical (Journey Medical) Piotroski F-Score : 6 (As of May. 07, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Journey Medical has an F-score of 6 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Journey Medical's Piotroski F-Score or its related term are showing as below:

DERM' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 6
Current: 6

During the past 5 years, the highest Piotroski F-Score of Journey Medical was 6. The lowest was 3. And the median was 5.


Journey Medical Piotroski F-Score Historical Data

The historical data trend for Journey Medical's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Piotroski F-Score Chart

Journey Medical Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
N/A N/A N/A 3.00 6.00

Journey Medical Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 N/A 3.00 5.00 6.00

Competitive Comparison of Journey Medical's Piotroski F-Score

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Journey Medical's Piotroski F-Score Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Journey Medical's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -10.136 + -8.363 + 16.789 + -2.143 = $-3.85 Mil.
Cash Flow from Operations was -0.956 + 3.969 + 18.747 + -16.52 = $5.24 Mil.
Revenue was 12.213 + 17.172 + 34.539 + 15.257 = $79.18 Mil.
Gross Profit was 5.764 + 9.405 + 28.11 + 9.242 = $52.52 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(105.16 + 95.853 + 69.747 + 65.918 + 76.849) / 5 = $82.7054 Mil.
Total Assets at the begining of this year (Dec22) was $105.16 Mil.
Long-Term Debt & Capital Lease Obligation was $14.63 Mil.
Total Current Assets was $56.46 Mil.
Total Current Liabilities was $41.87 Mil.
Net Income was -1.378 + -7.528 + -10.08 + -10.642 = $-29.63 Mil.

Revenue was 23.296 + 18.291 + 16.116 + 15.966 = $73.67 Mil.
Gross Profit was 15.093 + 10.658 + 8.895 + 8.248 = $42.89 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(97.284 + 120.901 + 113.496 + 108.145 + 105.16) / 5 = $108.9972 Mil.
Total Assets at the begining of last year (Dec21) was $97.28 Mil.
Long-Term Debt & Capital Lease Obligation was $19.93 Mil.
Total Current Assets was $77.68 Mil.
Total Current Liabilities was $66.83 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Journey Medical's current Net Income (TTM) was -3.85. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Journey Medical's current Cash Flow from Operations (TTM) was 5.24. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-3.853/105.16
=-0.03663941

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-29.628/97.284
=-0.30455162

Journey Medical's return on assets of this year was -0.03663941. Journey Medical's return on assets of last year was -0.30455162. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Journey Medical's current Net Income (TTM) was -3.85. Journey Medical's current Cash Flow from Operations (TTM) was 5.24. ==> 5.24 > -3.85 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=14.631/82.7054
=0.17690501

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=19.934/108.9972
=0.18288543

Journey Medical's gearing of this year was 0.17690501. Journey Medical's gearing of last year was 0.18288543. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=56.455/41.868
=1.34840451

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=77.679/66.832
=1.16230249

Journey Medical's current ratio of this year was 1.34840451. Journey Medical's current ratio of last year was 1.16230249. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Journey Medical's number of shares in issue this year was 19.324. Journey Medical's number of shares in issue last year was 17.766. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=52.521/79.181
=0.66330307

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=42.894/73.669
=0.58225305

Journey Medical's gross margin of this year was 0.66330307. Journey Medical's gross margin of last year was 0.58225305. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=79.181/105.16
=0.7529574

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=73.669/97.284
=0.7572571

Journey Medical's asset turnover of this year was 0.7529574. Journey Medical's asset turnover of last year was 0.7572571. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+1+1+1+1+1+0+1+0
=6

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Journey Medical has an F-score of 6 indicating the company's financial situation is typical for a stable company.

Journey Medical  (NAS:DERM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Journey Medical Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Journey Medical's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Journey Medical (Journey Medical) Business Description

Traded in Other Exchanges
N/A
Address
9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258
Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.
Executives
Jeffrey Paley director C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith director C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md director 375 PARK AVE, NEW YORK NY 10152
Claude Maraoui director, officer: President & CEO C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch officer: Interim CFO C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert officer: Chief Financial Officer 4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz director 2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135

Journey Medical (Journey Medical) Headlines

From GuruFocus

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

By Stock market mentor Stock market mentor 01-20-2023